Congressional Chairmen Ask CMS: Were 340B Providers Overcharged for EpiPens?

by Admin | December 12, 2016 1:52 pm

December 12, 2016—House and Senate committee leaders want the Centers for Medicare & Medicaid Services to answer questions about its handling of the anaphylaxis rescue drug EpiPen by Dec. 20, including whether EpiPen’s misclassification as a generic drug for Medicaid rebate purposes caused hospitals and other healthcare providers in the 340B drug discount program[1] to be overcharged. Meanwhile, a federal healthcare watchdog agency has launched three new investigations stemming from the EpiPen drug pricing scandal.  

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2016/12/congressional-chairmen-ask-cms-were-340b-providers-overcharged-for-epipens/

---